ALS drug gets rare second review

Matthew Perrone, Las Vegas Sun: September 7, 2022 This AP article was published in numerous newspapers and websites A closely watched experimental drug for Lou Gehrig’s disease got an unusual second look from U.S. regulators on Wednesday, following intense pressure to approve the treatment for those with the fatal illness. Patients and their families have […]

Read More »

Trump Covid Report Stirs Calls for FDA to Rebuild Public Trust

Celine Castronuovo and Jeannie Baumann, Bloomberg Law, August, 26, 2022 A House report detailing coordinated attempts by Trump White House officials to influence the FDA’s pandemic response underscores the need for more transparency at an agency that’s facing historically low public trust, health policy analysts say. The House Select Subcommittee on the Coronavirus Crisis said this […]

Read More »

Bipartisan bill on antibiotics faces crucial stretch

The Hill, August 1, 2022: A health care bill is facing criticism from some experts who say it could lead to huge spending on new antibiotic drug development that may not improve patient outcomes in the long run. We point out that it could increase antibiotic resistance rather than solve the problem.

Read More »